Gain Therapeutics (NASDAQ:GANX - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.18) by $0.07, Zacks reports.
Gain Therapeutics Price Performance
Shares of NASDAQ GANX traded down $0.09 during mid-day trading on Tuesday, hitting $1.82. 112,001 shares of the stock were exchanged, compared to its average volume of 281,121. The company has a market cap of $48.28 million, a P/E ratio of -1.66 and a beta of 0.14. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.99 and a current ratio of 2.99. Gain Therapeutics has a twelve month low of $0.89 and a twelve month high of $4.04. The stock's fifty day simple moving average is $2.21 and its two-hundred day simple moving average is $2.07.
Analyst Upgrades and Downgrades
A number of research analysts recently commented on the company. Roth Capital raised Gain Therapeutics to a "strong-buy" rating in a research report on Thursday, December 5th. Roth Mkm reaffirmed a "buy" rating and set a $7.00 price objective on shares of Gain Therapeutics in a report on Tuesday, December 24th. Chardan Capital reissued a "buy" rating and issued a $6.00 target price on shares of Gain Therapeutics in a research note on Friday. Scotiabank initiated coverage on shares of Gain Therapeutics in a research note on Friday, March 7th. They set a "sector outperform" rating and a $12.00 price target for the company. Finally, HC Wainwright reissued a "buy" rating and issued a $8.00 target price on shares of Gain Therapeutics in a report on Monday, March 17th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $8.20.
Read Our Latest Analysis on Gain Therapeutics
Gain Therapeutics Company Profile
(
Get Free Report)
Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
See Also
Before you consider Gain Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gain Therapeutics wasn't on the list.
While Gain Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
